[Federal Register Volume 65, Number 34 (Friday, February 18, 2000)]
[Notices]
[Pages 8384-8385]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-4009]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Uteroglobin in Treatment 
of IgA Mediated Autoimmune Disorders

AGENCY: National Institutes of Health, Public Health Services, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive license worldwide to practice the invention embodied in: 
U.S. Patent Application Serial No. 60/130,434, filed April 21, 1999 
entitled, ``Uteroglobin in Treatment of IgA Mediated Autoimmune 
Disorders'' to Claragen, Inc., having a place of business in Silver 
Spring, MD. The patent rights in this invention have been assigned to 
the United States of America.

DATE: Only written comments and/or application for a license which are 
received by the NIH Office of Technology Transfer on or before May 18, 
2000.

ADDRESS: Requests for a copy of the patent applications, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Dennis H. Penn, Pharm.D., Technology Licensing 
Specialist, Office

[[Page 8385]]

of Technology Transfer, National Institutes of Health, 6011 Executive 
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-
7056, ext. 211; Facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: Uteroglobin plays a significant role in 
human renal disease through its effect on the deposition of IgA. This 
invention relates to the use of uteroglobin and its role in the 
diagnosis and treatment of IgA nephropathy.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 90 days 
from the date of this published Notice, NIH received written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    The field of use may be limited to the use of the invention for the 
development of therapeutic and diagnostic applications relating to IgA 
nephropathy.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: February 14, 2000.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 00-4009 Filed 2-17-00; 8:45 am]
BILLING CODE 4140-01-M